Healthcare / BiotechnologyNasdaqCM
$6.85
-0.36 (-4.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-51.7M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$718M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-66.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-57.4M · FCF $-45.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $7941.00 |
| Net Income | $-57.4M | $-57.4M | $-80.0M | $-98.8M | $-157.0M | $-125.8M | $-59.5M | $-15.0M | $-9.0M | $-6.3M | $-3.0M | $-20.8M | — | $-19.9M | $-12052.00 |
| EBITDA | $-59.1M | $-59.1M | $-83.9M | $-103.7M | $-161.2M | — | — | — | — | — | — | — | — | — | — |
| EPS | -1.45 | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 27.0% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -151.8% |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -151.8% |
| Balance Sheet | |||||||||||||||
| Current Ratio | 80.21 | 80.21 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-45.8M | $-45.8M | $-51.8M | $-51.7M | $-103.8M | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -66.3% | -66.3% | -225.2% | -115.7% | -111.8% | -60.4% | -56.3% | -13.0% | 162.5% | -430.5% | -42.2% | -236.1% | — | 110.7% | -106.1% |
| Valuation | |||||||||||||||
| P/B | 3.13 | 3.13 | 0.40 | 1.17 | 0.69 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| EPS Growth | 45.3% | 45.3% | 19.2% | 38.1% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+813.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.65 → -1.45
Residual
+813.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.